|A unique collection of 81 Cardioprotective natural compounds for high throughput screening (HTS) and high content screening (HCS).|
|Catalog No:||Bb1313|| Cardioprotective Compound Library
|Size:||1mg/well * 81 Compounds|
2mg/well * 81 Compounds
Ursolic acid is a potential PPARγagonist, which has anti-tumor, chemopreventive, hepatoprotective, anti-inflammatory, antioxidant, antidepressant-like, antimicrobial activities, and anti-asthmatic effects. Ursolic acid also has antihyperlipidemic, hypoglycemic and direct cardiac effect, its antihypertensive effect is attributed to its potent diuretic-natriuretic-saluretic activity. Ursolic acid regulates NF-κB, VEGF, COX-2, Nrf2, ARE, IL-5, IL-13, IL-17and MAPK signaling pathways.
Visnagin has acute hypotensive, anti-inflammatory, and neuroprotective effects, it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Visnagin can relax aortae previously contracted by noradrenaline, and weakly inhibit the hydrolytic activity of the cyclic nucleotide phosphodiesterase (PDE) isozymes (PDE5, PDE4, PDE3, cyclic GMP activated PDE2 and PDE1).
Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM, and is also a potent inhibitor of CYP1A2. Rutaecarpine has anti-atherosclerosis, immunosuppressive, anti-inflammatory, gastroprotective, vasorelaxing, antihypertensive and anti-platelet effects. Rutaecarpine has positive inotropic and chronotropic effects on the guinea-pig isolated right atria, possible involvement of vanilloid receptors. Rutaecarpine may be useful in the prevention of ultraviolet A-induced photoaging, it inhibits ultraviolet A-induced reactive oxygen species generation, resulting in the enhanced expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human skin cells.
Nardosinone is an enhancer of nerve growth factor and possesses a wide range of pharmacological effects, including sedative, adaptogen-like, anti-depressive, anti-leukemic, anti-tumorous, and anti-trypanosomal activities. It has a wide spectrum of targets including PI3K,Akt,MEK,ERK, PKA, MAPK.
Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. Glaucocalyxin A has regulation of microglia activity, can attenuate lipopolysaccharide -stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways.Glaucocalyxin A may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management, it can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production.